Successful management of denosumab discontinuation in a patient with primary pediatric osteoporosis

Key Points

• Management of denosumab discontinuation led to successful outcomes in osteoporosis.
• Key metrics show improvement in bone density over six months without side effects.
• Observational analysis documented treatment changes and patient responses in pediatric cases.
• Findings underline the need for individualized treatment plans for young patients with osteoporosis.